Jingcao Huang

Institute of Hematology, Sichuan University

Research Area

Biography

Jingcao Huang has not added Biography.
If you are Jingcao Huang and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 1	2024
Publication title	2025

Other Publications

Article	Year
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. Journal of hematology & oncology\| PubMed ID: 27855695	2016
Therapeutic effect of 28-homobrassinolide on leukotriene synthesis in leukemia cells. Cytotechnology\| PubMed ID: 29101583	2018
Epigenetic mechanism of survivin dysregulation in human cancer. Science China. Life sciences\| PubMed ID: 29318497	2018
Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer letters\| PubMed ID: 29409974	2018
Young female patients with multiple myeloma have low occurrence of osteolytic lesion. Bone\| PubMed ID: 29414597	2018
Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34 cells. Stem cell research & therapy\| PubMed ID: 29895317	2018
Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells. Biological procedures online\| PubMed ID: 30093840	2018
Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors-a Study in Leukemia Cell... Nanoscale research letters\| PubMed ID: 30191515	2018
SLC2A5 overexpression in childhood philadelphia chromosome-positive acute lymphoblastic leukaemia. British journal of haematology\| PubMed ID: 30272826	2018
[Molecular Characteristics and Clinical Features of Adults with Fusions in Acute Myeloid Leukemia]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition\| PubMed ID: 30378313	2018
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy. Immunotherapy\| PubMed ID: 30606076	2019
Wharton's jelly mesenchymal stem cell-based or umbilical vein endothelial cell-based serum-free coculture with cytokines supports the ex vivo expansion/maintenance of cord blood hematopoieti... Stem cell research & therapy\| PubMed ID: 31806004	2019
PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells. OncoTargets and therapy\| PubMed ID: 32764981	2020
Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating . American journal of translational research\| PubMed ID: 32774712	2020
High Wilms' tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates mA methylation of MYC mRNA. Journal of cancer research and clinical oncology\| PubMed ID: 32880751	2021
Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway. Biochemical pharmacology\| PubMed ID: 33831397	2021
BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. Cell death & disease\| PubMed ID: 33993198	2021
Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma. Frontiers in oncology\| PubMed ID: 34268123	2021
ALCAM-EGFR interaction regulates myelomagenesis. Blood advances\| PubMed ID: 34592762	2021
Minimal residual disease in multiple myeloma: current status. Biomarker research\| PubMed ID: 34649622	2021
Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing. Advanced materials (Deerfield Beach, Fla.)\| PubMed ID: 34877715	2022
Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research\| PubMed ID: 35064934	2022
ALCAM regulates multiple myeloma chemoresistant side population. Cell death & disease\| PubMed ID: 35145058	2022
Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia. American journal of cancer research\| PubMed ID: 35812060	2022
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5. JCI insight\| PubMed ID: 36040812	2022
A novel immune prognostic model of non-M3 acute myeloid leukemia. American journal of translational research\| PubMed ID: 36105048	2022
Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity. ACS omega\| PubMed ID: 36643473	2023
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. Cancer letters\| PubMed ID: 37149018	2023
Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma. Life sciences\| PubMed ID: 37805164	2023
RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor. Cancer letters\| PubMed ID: 37984724	2024
Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide. British journal of haematology\| PubMed ID: 38685577	2024
Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition. The journal of gene medicine\| PubMed ID: 38949072	2024
Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib. Cell death & disease\| PubMed ID: 39138149	2024
Ferroptosis-related prognostic model of mantle cell lymphoma. Open medicine (Warsaw, Poland)\| PubMed ID: 39588389	2024